(Date:7/2/2008)... develops new therapies based on cells manufacture.../S provide funding round, SALT LAKE CITY and HAMB..., a biotechnology company at the forefront of inno...idney injury, today announced the closing of a,$14...ife Sciences with Novo,A/S joining the syndicate.,...
(Date:7/2/2008).../- Aureus Pharma, a leading provider ...scovery in the life science,industry, announced to...l,be held in Paris on October 23rd and 24th., Thi...inaugural event,which was attended by many of Aure... Europe and North America. The symposium included ...
(Date:7/2/2008)...ance Commercialization of Expanded Portfolio of Va...ANCOUVER, British Columbia, July 2 /-...es Corp. (TSXV: MEV), a company developing and,mar...y announced its name,change and the expansion of i... acquisition of two vascular product development c...
(Date:7/2/2008)...ts to potential of pre-treatment R2 levels as a po...tivity -, TORONTO, July 2 /PRNewswire-FirstCall/ ...Lorus" or the "Corporation"), a biopharmaceutical ...nt of pharmaceutical products and,technologies for...tion by,an Ohio State University (OSU) clinical te...
Breaking Biology Technology:AlloCure Inc. Closes $14.5MM Series A Round to Develop a Stem Cell Therapy for Acute Kidney Injury 2AlloCure Inc. Closes $14.5MM Series A Round to Develop a Stem Cell Therapy for Acute Kidney Injury 3Aureus Pharma Announces Date of 2008 Annual User Symposium 2Medical Ventures Becomes Neovasc with Two Corporate Acquisitions and $8.3 Million Financing 2Medical Ventures Becomes Neovasc with Two Corporate Acquisitions and $8.3 Million Financing 3Medical Ventures Becomes Neovasc with Two Corporate Acquisitions and $8.3 Million Financing 4Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML) 2Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML) 3Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML) 4Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML) 5... , , , , , Here are some ... regarding misincorporation or low fidelity of... , , , , ... , , <a , ...igh , , , , ...
..., , , for routine high fidelity am..., Cat. No. 1 664 947 , 100 units ,..., , , , , , , Descripti... was originally isolated from hyperthermophilic ,...zyme has a molecular weight of , about 90...
... , for routine amplification of up to 3 kb g...0 reactions) , , , , , , ...contains 10 vials of 2x concentrated PCR reaction ...with MgCl 2 , stabilizing , detergent, dNTP... for 100 , PCR reactions. Taq DNA Polymeras...
..., , for amplification of up to 5 kb targ...00 reactions , , , , , , ...trated High Fidelity PCR Master contains all neces...nzymes) needed for PCR. The mix contains , ...o DNA Polymerase[a thermostable , enzyme wi...
Other Biology Technology:Trouble-shooting: Misincorporation or low fidelity 2Trouble-shooting: Misincorporation or low fidelity 3Pwo DNA Polymerase 2Pwo DNA Polymerase 3PCR Master 2PCR Master 3High Fidelity PCR Master 2(Date:7/2/2008)...AHASSEE, Fla. -- A Florida State University facult...uate a new class of cancer-killing drugs is attrac..., Kevin C. Chen, an assistant professor of chemic...niversity-Florida State University College of Engi...ine how substances known as recombinant immunotoxi...
(Date:7/2/2008)...ON D.C. World Wildlife Fund (WWF) is alarmed by th...engal tiger population of Suklaphanta Wildlife Res...e highest densities of the endangered species in t...008 showed a population of between 6-14 tigers, do...of Nepal made a low-key announcement on July 1 bas...
(Date:7/2/2008)...REEK, CAIn the continuing effort to tap the vast, ...ant domains for bioenergy and environmental applic...as announced its latest portfolio of DNA sequencin...ar. The 44 projects, culled from nearly 150 propos...ram (CSP), represent over 60 billion nucleotides o...
(Date:7/2/2008)...rks, North Dakota, July 2, 2008 Volunteers repres...nternational (JDRF), the American Diabetes Associa...IHB) will present Senator Byron Dorgan with the 20...ip on extending the Special Diabetes Program (SDP)....m. in the Buchli Room at the Hilton Garden Inn in...
Breaking Biology News(10 mins):FSU researcher using computers to hone cancer-fighting strategies 2Tigers disappear from Himalayan refuge 2US Department of Energy Joint Genome Institute announces new genome sequencing projects 2US Department of Energy Joint Genome Institute announces new genome sequencing projects 3US Department of Energy Joint Genome Institute announces new genome sequencing projects 4US Department of Energy Joint Genome Institute announces new genome sequencing projects 5US Department of Energy Joint Genome Institute announces new genome sequencing projects 6US Department of Energy Joint Genome Institute announces new genome sequencing projects 7Sen. Byron Dorgan to be honored 2Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer 1282 1Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer 1282 2Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer 1282 3Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer 1282 4ChemDiv and Achaogen Enter Into a Discovery Collaboration 2807 1ChemDiv and Achaogen Enter Into a Discovery Collaboration 2807 2Surface Logix Achieves Objectives With SLx 4090 in Phase 2a Clinical Trial 2803 1Surface Logix Achieves Objectives With SLx 4090 in Phase 2a Clinical Trial 2803 2Surface Logix Achieves Objectives With SLx 4090 in Phase 2a Clinical Trial 2803 3Surface Logix Achieves Objectives With SLx 4090 in Phase 2a Clinical Trial 2803 4Inverseon Announces Positive Phase IIa Asthma Study 1281 1Inverseon Announces Positive Phase IIa Asthma Study 1281 2...t time, you can identify and characterize high-val...tly without interferences. The Agilent Multiple Af...d, multiple high-abundant proteins from human seru...ice. With this revolutionary system, you can: Re...
...olor RNA Spike-In Kit contains in vitro synthesize...neal only to complementary control probes on Agile...dization. The spike-ins serve as a positive microa...TE: This kit is a required component of the Agilen...
...e one mouse-click image analysis software for micr...is the solution for high quality and high throughp...ith VigeneTechs robust algorithms, actual spot bou...ckground correction and dust removal, enhancing th...
...eomic Imaging System, Professional Package Superi...Dynamic Range: The ProXPRESS 2D Proteomic Imaging ... both proteomic and general life science research ...lexibility, enabling the use of all dyes in the UV...
Biology Products: